<?xml version="1.0" encoding="UTF-8"?>
<p>The studies included in the SR are recent, from 2005 on, which indicates that these studies of costs of dengue may be of growing interest for the inclusion of preventive interventions. One example is the dengue vaccine, which in recent years has arisen several candidates in pre-clinical and clinical developmental stages against the four serotypes of the dengue virus [
 <xref rid="pone.0211401.ref039" ref-type="bibr">39</xref>; 
 <xref rid="pone.0211401.ref040" ref-type="bibr">40</xref>] an example is Dengvaxia (CYD-TDV) from Sanofi Pasteur, the first live quadrivalent recombinant live vaccine registered in 2015 [
 <xref rid="pone.0211401.ref041" ref-type="bibr">41</xref>]. WHO recommends the inclusion of such intervention to countries that present epidemiological data indicating the economic burden of the disease [
 <xref rid="pone.0211401.ref041" ref-type="bibr">41</xref>], thus using these SR studies for cost-effectiveness calculations [
 <xref rid="pone.0211401.ref038" ref-type="bibr">38</xref>].
</p>
